$1.57 Billion is the total value of NEA Management Company, LLC's 34 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was 25.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TSRO | TESARO INC | $463,255,000 | +30.5% | 8,854,255 | 0.0% | 29.49% | +26.1% | |
| ARDX | ARDELYX INC | $186,529,000 | +4.9% | 10,294,096 | 0.0% | 11.87% | +1.3% | |
| GRPN | GROUPON INC | $135,611,000 | -5.8% | 44,172,953 | 0.0% | 8.63% | -9.0% | |
| DERM | DERMIRA INC | $121,365,000 | +48.3% | 3,506,649 | 0.0% | 7.72% | +43.3% | |
| OPWR | OPOWER INC | $95,011,000 | +18.5% | 8,997,290 | 0.0% | 6.05% | +14.5% | |
| EPZM | EPIZYME INC | $82,499,000 | +24.6% | 5,149,740 | 0.0% | 5.25% | +20.4% | |
| NVRO | NEVRO CORP | $67,066,000 | +45.5% | 993,428 | 0.0% | 4.27% | +40.6% | |
| LOXO | LOXO ONCOLOGY INC | $50,988,000 | +62.8% | 1,792,207 | 0.0% | 3.25% | +57.3% | |
| GLYC | Buy | GLYCOMIMETICS INC | $49,101,000 | +2.2% | 8,584,118 | +0.1% | 3.12% | -1.2% |
| TRVN | Sell | TREVENA INC | $40,023,000 | -19.6% | 3,811,691 | -20.8% | 2.55% | -22.3% |
| CLVS | CLOVIS ONCOLOGY INC | $39,896,000 | -61.9% | 1,139,890 | 0.0% | 2.54% | -63.2% | |
| LXRX | New | LEXICON PHARMACEUTICALS INC | $31,708,000 | – | 2,382,286 | +100.0% | 2.02% | – |
| TRIV | TRIVASCULAR TECHNOLOGIES INC | $26,236,000 | +33.0% | 3,945,191 | 0.0% | 1.67% | +28.5% | |
| HIVE | AEROHIVE NETWORKS INC | $23,922,000 | -14.5% | 4,681,455 | 0.0% | 1.52% | -17.4% | |
| CRCM | CARE COM INC | $23,349,000 | +39.3% | 3,260,989 | 0.0% | 1.49% | +34.6% | |
| MIRN | New | MIRNA THERAPEUTICS INC | $18,593,000 | – | 2,974,811 | +100.0% | 1.18% | – |
| TCON | TRACON PHARMACEUTICALS INC | $17,460,000 | -5.4% | 1,889,652 | 0.0% | 1.11% | -8.6% | |
| SBBP | New | STRONGBRIDGE BIOPHARMA PLC | $16,274,000 | – | 2,141,308 | +100.0% | 1.04% | – |
| EXEL | EXELIXIS INC | $12,447,000 | +0.5% | 2,207,000 | 0.0% | 0.79% | -2.9% | |
| RIGL | RIGEL PHARMACEUTICALS INC | $9,827,000 | +22.7% | 3,243,150 | 0.0% | 0.63% | +18.6% | |
| SNSS | Buy | SUNESIS PHARMACEUTICALS INC | $7,011,000 | +52.1% | 7,789,644 | +36.9% | 0.45% | +46.7% |
| ABIO | ARCA BIOPHARMA INC | $6,790,000 | -6.3% | 1,460,209 | 0.0% | 0.43% | -9.4% | |
| OREX | OREXIGEN THERAPEUTICS INC | $6,379,000 | -18.5% | 3,709,000 | 0.0% | 0.41% | -21.3% | |
| AUPH | AURINIA PHARMACEUTICALS INC | $6,291,000 | -13.0% | 2,546,843 | 0.0% | 0.40% | -16.1% | |
| CSBR | CHAMPIONS ONCOLOGY INC | $5,578,000 | -33.3% | 1,562,500 | 0.0% | 0.36% | -35.6% | |
| ARQL | ARQULE INC | $5,469,000 | +16.0% | 2,520,316 | 0.0% | 0.35% | +11.9% | |
| ZSAN | ZOSANO PHARMA CORP | $4,921,000 | -42.4% | 2,158,543 | 0.0% | 0.31% | -44.4% | |
| ZHNE | ZHONE TECHNOLOGIES INC | $4,781,000 | -27.0% | 4,781,290 | 0.0% | 0.30% | -29.6% | |
| ROKA | ROKA BIOSCIENCE INC | $3,961,000 | -36.9% | 3,220,433 | 0.0% | 0.25% | -39.1% | |
| PRTK | PARATEK PHARMACEUTICALS INC | $2,371,000 | -0.2% | 125,004 | 0.0% | 0.15% | -3.2% | |
| CBIO | CATALYST BIOSCIENCES INC | $2,042,000 | -32.8% | 652,380 | 0.0% | 0.13% | -35.0% | |
| AKTX | Buy | AKARI THERAPEUTICS PLCadr | $1,769,000 | +174.3% | 121,970 | +353.5% | 0.11% | +169.0% |
| AGRX | AGILE THERAPEUTICS INC | $1,303,000 | +44.8% | 133,488 | 0.0% | 0.08% | +40.7% | |
| CERC | New | CERECOR INC | $1,195,000 | – | 595,435 | +100.0% | 0.08% | – |
| ECOM | Exit | CHANNELADVISOR CORP | $0 | – | -556,692 | -100.0% | -0.36% | – |
| CVT | Exit | CVENT INC | $0 | – | -244,106 | -100.0% | -0.54% | – |
| MM | Exit | MILLENNIAL MEDIA INC | $0 | – | -8,224,752 | -100.0% | -0.95% | – |
| LXRX | Exit | LEXICON PHARMACEUTICALS INC | $0 | – | -2,382,286 | -100.0% | -1.69% | – |
| SUPN | Exit | SUPERNUS PHARMACEUTICALS INC | $0 | – | -7,641,250 | -100.0% | -7.06% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-01-22
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GLYCOMIMETICS INC | 39 | Q3 2023 | 7.6% |
| AURINIA PHARMACEUTICALS INC | 37 | Q3 2023 | 5.0% |
| CHAMPIONS ONCOLOGY INC | 33 | Q3 2023 | 1.2% |
| LEXICON PHARMACEUTICALS INC | 32 | Q3 2023 | 2.0% |
| ADAPTIMMUNE THERAPEUTICS PLC | 31 | Q3 2023 | 9.3% |
| TREVENA INC | 31 | Q3 2021 | 3.3% |
| AKARI THERAPEUTICS PLC | 31 | Q2 2023 | 0.3% |
| ARDELYX INC | 29 | Q3 2021 | 11.9% |
| RIGEL PHARMACEUTICALS INC | 29 | Q2 2020 | 0.6% |
| EPIZYME INC | 28 | Q1 2020 | 9.6% |
View NEA Management Company, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-10 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-12 |
View NEA Management Company, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.